STRC Research

GeneReviews — STRC-Related Hearing Loss (DFNB16)

2 min read

GeneReviews — STRC-Related Hearing Loss (NBK598310)

Source: NIH GeneReviews, NBK598310
URL: https://www.ncbi.nlm.nih.gov/books/NBK598310/
Type: Authoritative clinical review

Key Ideas

  • DFNB16 hearing loss is mild-to-moderate at onset. Stable in 75% of ears longitudinally. This is not a progressive sensorineural loss in the way that KCNQ4 or mitochondrial diseases are.
  • Average annual progression: 0.6 dB/year across the cohort. That’s clinically negligible. For comparison, normal age-related hearing loss in adults runs 0.5-1 dB/year — DFNB16 is on par.
  • 96% of patients remain at moderate severity or better over 6+ years. The severe/profound tail exists but is the minority.
  • OHC bodies remain alive long-term. The hearing loss is structural (missing horizontal top connectors) not degenerative (dying cells). This is the mechanistic basis for why gene therapy can work at any age.
  • Compound heterozygous (like Misha: paternal deletion + maternal missense) vs biallelic deletion: no significant phenotypic difference in audiometric outcomes. Misha’s genotype doesn’t put him in a worse prognostic category than full deletion patients.

My Thoughts

This is the most authoritative natural history document and the one to share with audiologists who don’t know DFNB16 specifically. The 0.6 dB/year progression rate and 75% stability figure directly counter the catastrophizing framing some families receive.

The OHC survival point is the most clinically important. Most acquired sensorineural hearing loss involves OHC death (noise damage, aminoglycosides, age) — those are irreversible because the cells are gone. DFNB16 is different. The structural protein is missing but the cell is alive. That’s why gene therapy, pharmacochaperones, and other protein-delivery strategies are viable here when they wouldn’t be for a dead-cell pathology.

For Misha specifically: his compound het genotype (paternal 98 kb deletion + maternal E1659A) is in the database and shows no worse outcomes than biallelic deletion. His baseline audiogram at diagnosis is the right time anchor, not a reason for additional alarm.

Connections

Graph View

Backlinks